期刊文献+

结直肠癌肝转移的发生机制 被引量:10

Molecular Mechanism of Liver Metastasis from Colorectal Cancer
下载PDF
导出
摘要 结直肠癌的发病率及死亡率在全世界以每年递增的趋势发展着,而其主要的死亡原因是肝转移。这一事件引起了众多学者的关注,大量研究也从各方面对其机理进行了论证。我们应用PubMed和MedLine,以及中国期刊网全文数据库(CNKI)两大文献检索文库,用"结直肠癌"、"肝转移"、"分子机制"等关键词进行检索,总结了近十年间有关结直肠癌的研究,试图提供一个结直肠癌肝转移的基本框架。本文中重点分析一些可能控制此事件的关键分子,对8类13项分子指标,包括基质金属蛋白酶、尿激酶型纤溶酶原激活剂受体、整合素、骨桥蛋白、肿瘤坏死因子相关凋亡诱导配体、干扰素-β、胰岛素样生长因子Ⅰ型受体、核基质蛋白、血管上皮生长因子、过氧化物酶体增殖物激活受体、胰岛素样生长因子、细胞外信号调节激酶和蛋白酶活化受体等与结直肠癌之间的关系进行了总结和分析,以期为寻找治疗和预测结直肠癌肝转移的新靶点提供新思路。 The morbidity and mortality of colorectal cancer are increasing over the world, while liver metastasis is the main cause of death. Many studies have elucidated the mechanisms. We searched the key words, such as colorectal cancer, liver metastasis and molecular factors, through PubMed, Medline and National Knowledge Infrastructure CNKI literature searching system, and discussed the studies in the recent decade. Thirteen well-identified and elucidated molecular factors, which belong to 8 categories, including matrix metalloproteinases, urokinase plasminogen activator receptor, intergin, osteopontin, tumor necrosis factor-related apoptosis-inducing ligand, interferon-β, insulin-like growth factor receptor 1, nuclear matrix protein, vascular endothelial growth factor, peroxisome proliferator-activated receptor-gamma, insulin-like growth factor, extracellular signal-regulated protein kinase and proteinase-activated receptors were reviewed in the article. Correlations of these molecular factors to colorectal cancer were summarized, which maybe helpful to give a new insight into the treatment and prediction of colorectal cancer with liver metastasis.
出处 《癌症》 SCIE CAS CSCD 北大核心 2008年第5期549-554,共6页 Chinese Journal of Cancer
关键词 结直肠肿瘤 肝肿瘤/继发性 分子机制 Colorectal neoplasm Liver neoplasm/secondary Molecularmechanism
  • 相关文献

参考文献60

  • 1万德森,陈功.结直肠癌的流行病学及其危险因素研究近况[J].实用癌症杂志,2000,15(2):220-222. 被引量:103
  • 2夏振龙.大肠癌肝转移的发生率及临床特点[J].中国实用外科杂志,1999,19(10):579-579. 被引量:53
  • 3Paget S. The distribution of secondary growths in cancer of the breast [J]. Lancet, 1889,1:571-573.
  • 4Chambers A F, Groom A C, MacDonald I C. Dissemination and growth of cancer cells in metastatic sites [J]. Nat Rev Cancer, 2002,2 (8) :563-572.
  • 5Hidalgo M, Eckhardt S G. Development of matrix metalloproteinase inhibitors in cancer therapy [J]. J Natl Cancer Inst,2001,93(3):178-193.
  • 6d'Ortho M P, Will H, Atkinson S, et al. Membrane-type matrix metalloproteinases 1 and 2 exhibit broad-spectrum proteolytic capacities comparable to many matrix metalloproteinases [J]. Eur J Biochem, 1997,250(3) : 751-757.
  • 7Lievre A, Milet J, Carayol J, et al. Genetic polymorphisms of MMP1, MMP3 and MMP7 gene promoter and risk of colorectal adenoma [J]. BMC Cancer, 2006,6:270.
  • 8Oba K, Konno H, Tanaka T, et al. Prevention of liver metastasis of human colon cancer by selective matrix metalloproteinase inhibitor MMI-166[J]. Cancer Lett, 2002,175 (1):45- 51.
  • 9Ishizaki T, Katsumata K, Tsuchida A, et al. Etodolac, a selective cyclooxygenase-2 inhibitor, inhibits liver metastasis of colorectal cancer cells via the suppression of MMP-9 activity [J]. Int J Mol Med, 2006,17 (2) : 357-362.
  • 10Beaucher M, Hersperger E, Page- McCaw A, et al. Metastatic ability of Drosophila tumors depends on MMP activity [J]. Dev Biol, 2007,303(2): 625-634.

二级参考文献34

共引文献249

同被引文献131

引证文献10

二级引证文献44

相关作者

内容加载中请稍等...

相关机构

内容加载中请稍等...

相关主题

内容加载中请稍等...

浏览历史

内容加载中请稍等...
;
使用帮助 返回顶部